Discovery Capital Management LLC CT Invests $2.47 Million in BioNTech SE (NASDAQ:BNTX)

Discovery Capital Management LLC CT acquired a new position in shares of BioNTech SE (NASDAQ:BNTX) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 30,700 shares of the company’s stock, valued at approximately $2,467,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in BNTX. GAMMA Investing LLC increased its holdings in shares of BioNTech by 121.0% during the first quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock worth $25,000 after buying an additional 150 shares in the last quarter. Covestor Ltd increased its stake in shares of BioNTech by 47.2% in the first quarter. Covestor Ltd now owns 415 shares of the company’s stock valued at $38,000 after buying an additional 133 shares during the period. EverSource Wealth Advisors LLC grew its holdings in BioNTech by 106.3% during the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock worth $43,000 after acquiring an additional 252 shares during the last quarter. Crewe Advisors LLC acquired a new position in BioNTech in the 1st quarter valued at approximately $75,000. Finally, American National Bank acquired a new position in shares of BioNTech during the first quarter worth $81,000. Institutional investors own 15.52% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on BNTX. HC Wainwright reaffirmed a “buy” rating and set a $113.00 target price on shares of BioNTech in a research report on Monday, September 16th. TD Cowen lowered their price objective on BioNTech from $98.00 to $85.00 and set a “hold” rating for the company in a research report on Tuesday, August 6th. Hsbc Global Res upgraded BioNTech from a “hold” rating to a “strong-buy” rating in a report on Friday, August 2nd. HSBC raised shares of BioNTech from a “hold” rating to a “buy” rating in a research report on Friday, August 2nd. Finally, Jefferies Financial Group raised shares of BioNTech from a “hold” rating to a “buy” rating and upped their price objective for the company from $96.00 to $150.00 in a research note on Tuesday, September 17th. Six research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $124.54.

BioNTech Price Performance

Shares of NASDAQ:BNTX opened at $112.28 on Monday. The firm has a market capitalization of $26.69 billion, a price-to-earnings ratio of 224.56 and a beta of 0.23. The stock’s 50 day moving average is $90.81 and its 200-day moving average is $90.62. The company has a quick ratio of 7.40, a current ratio of 7.54 and a debt-to-equity ratio of 0.01. BioNTech SE has a twelve month low of $76.53 and a twelve month high of $131.49.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Monday, August 5th. The company reported ($3.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.02) by ($1.34). The business had revenue of $128.70 million for the quarter, compared to analyst estimates of $134.98 million. BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. The firm’s quarterly revenue was down 23.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.86) earnings per share. Sell-side analysts forecast that BioNTech SE will post -2.8 EPS for the current fiscal year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.